Alcresta

21 articles about Alcresta

• Alcresta Therapeutics Announces Publication of Cystic Fibrosis Foundation Position Paper Confirming Inline Enzyme Cartridges are Safe and Effective

  7/25/2023

  Alcresta Therapeutics, Inc. today announced the publication of a position paper in the May issue of the Journal of Cystic Fibrosis.

• Alcresta Therapeutics Announces Preclinical Data Showing ALC-078 Cartridge Use in SBS Model Associated with Reduced Dependence on Parenteral Nutrition

  3/16/2023

  Alcresta Therapeutics, Inc. today announced publication of preclinical data from the company's development device ALC-078 in a porcine short bowel syndrome (SBS) model.

• Alcresta Therapeutics Announces Series of Commercial Milestone Achievements for RELiZORB®

  4/1/2022

  Alcresta Therapeutics, Inc. today announced a series of commercial milestone achievements.

• Alcresta Therapeutics Announces Appointment of Chris Parrish as Chief Operations Officer

  11/29/2021

  Alcresta Therapeutics, Inc. announced the appointment of Chris Parrish as its Chief Operations Officer (COO) effective November 29, 2021.

• Alcresta Therapeutics Announces Medicare Local Coverage Determination that Confirms Coverage for RELiZORB®

  9/7/2021

  Alcresta Therapeutics, Inc. today announced that the Centers for Medicare & Medicaid Services (CMS) has published a Local Coverage Determination (LCD) on enteral nutrition (LCD ID No. 38955) that confirms coverage for RELiZORB® (immobilized lipase).

• Alcresta Therapeutics Announces Publication of Consensus Statement Supporting Access to RELiZORB®

  6/25/2019

  Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the publication of a consensus statement supporting the clinical outcomes of RELiZORB® and advocating for improved payer coverage and patient access.

• Data from the ASSURE Study of Long-Term Use of RELiZORB® Published in Journal of Pediatric Gastroenterology and Nutrition

  8/2/2018

  Largest Prospective Trial of Enteral Feeding in Cystic Fibrosis Shows Sustained Use of RELiZORB Can Help Hydrolyze Fatty Acids and Normalize Absorption

• Alcresta Therapeutics Announces RELiZORB® iMMOBILIZED LIPASE CARTRIDGE has been Issued a Unique Q-Code (Q9994) by CMS

  6/19/2018

  RELiZORB CARTRIDGE is an in-line digestive enzyme cartridge and is indicated for use in pediatric patients and adult patients to hydrolyze fats in enteral formula.

• Alcresta Therapeutics Presented Results at the North American Cystic Fibrosis Conference from the ASSURE Study: An Evaluation of the Long-Term Use of RELiZORB

  11/6/2017

  Data from the ASSURE study was shared at the North American Cystic Fibrosis Conference that took place November 2-4, 2017 in Indianapolis.

• Alcresta Receives New Innovative Technology Contract From Vizient, Inc. For Relizorb (Immobilized LIPASE) Cartridge

  9/20/2017

• Alcresta Announces Positive Results, Relizorb Increased Fat Absorption In Both Adult And Pediatric Patients With Cystic Fibrosis Receiving Enteral Nutrition

  7/31/2017

• Alcresta Snags FDA 510(K) Clearance for Use Of Relizorb in Kids

  7/20/2017

• Alcresta' RELiZORB Increases Fat Absorption In Adult And Pediatric Patients With Cystic Fibrosis Receiving Enteral Nutrition

  10/31/2016

• Bridgemedica And Alcresta Honored As Gold Winners In The 2016 Medical Design Excellence Award (MDEA)

  8/1/2016

• Alcresta Release: RELiZORB Recognized For Medical Design Excellence

  7/28/2016

• Alcresta Launches RELiZORB In The U.S.

  6/7/2016

• Alcresta To Present At The 34th Annual J.P. Morgan Healthcare Conference

  1/6/2016

• Alcresta Receives FDA Clearance For RELiZORB

  12/2/2015

• Alcresta Appoints Russell Clayton, D.O., Chief Medical Officer

  7/22/2015

• Alcresta Appoints John H. Tucker To Chief Executive Officer

  5/14/2014